Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans

M. Uehara, H. Kishikawa, S. Isami, K. Kisanuki, Y. Ohkubo, N. Miyamura, T. Miyata, T. Yano, M. Shichiri

Department of Metabolic Medicine, Kumamoto University School of Medicine, Kumamoto, Japan

Summary The present study compared the effect on insulin sensitivity of ACE inhibitors with a sulphydryl group (captopril) or those without a sulphydryl group (delapril and enalapril) during the hyperinsulinaemic euglycaemic clamp test in both animal and clinical experiments. A possible contribution of bradykinin to the improvement of insulin sensitivity by ACE-inhibition was also studied. In healthy control and depancreatized dog experiments, administration of captopril either intravenously ($3.0 \text{ mmol} \cdot \text{kg}^{-1}$) or orally ($5.0 \text{ mmol} \cdot \text{kg}^{-1}$) increased insulin sensitivity indices and plasma bradykinin concentrations. In comparison, intravenous administration of an active metabolite of delapril ($3.0 \text{ mmol} \cdot \text{kg}^{-1}$) and oral administration of either delapril or enalapril ($5.0 \text{ mmol} \cdot \text{kg}^{-1}$) showed slight, but not significant increases in insulin sensitivity indices and plasma bradykinin concentrations. Infusion of a bradykinin antagonist (N- α -adamantanecetyl-D-Arg-[Hyp³,Thi^{5,8},D-Phe⁷]-bradykinin) ($0.5 \text{ nmol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) abolished the effect of captopril on insulin sensitivity. Furthermore, intravenous administration of bradykinin ($0.1 \text{ nmol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) increased insulin

sensitivity indices. In clinical experiments, insulin sensitivity indices decreased in the following order: normotensive healthy subjects, hypertensive non-diabetic patients, normotensive NIDDM patients and hypertensive NIDDM patients. In these four groups, oral administration of captopril ($2.0 \text{ mmol} \cdot \text{kg}^{-1}$) significantly increased insulin sensitivity indices, and a concomitant increase in plasma bradykinin concentrations was observed. By contrast, oral administration of enalapril or delapril showed slight, but not significant effects on insulin sensitivity indices and plasma bradykinin concentrations. From these studies, it is concluded that ACE inhibitors with a sulphydryl group have more potent action on the improvement in insulin sensitivity than those without a sulphydryl group. Bradykinin may also possibly be involved in the mechanism underlying the improvement in insulin sensitivity associated with ACE-inhibition. [Diabetologia (1994) 37: 300–307]

Key words Diabetes mellitus, hypertension, angiotensin converting enzyme inhibitor, sulphydryl group, insulin sensitivity, bradykinin.

Hypertension commonly occurs in patients with diabetes mellitus [1]. Although a number of antihypertensive drugs are currently available for the treatment of hy-

pertension, most of these drugs, except for ACE inhibitors, α -adrenergic blockers and Ca^{2+} -channel blockers, are known to impair glucose metabolism [2]. Therefore, ACE inhibitors are often used to treat hypertension associated with diabetes because of their manageability, efficacy and low frequency of side effects.

Currently available ACE inhibitors can be divided into two categories: those with a sulphydryl group (captopril) or those without a sulphydryl group (enalapril and delapril) [3]. The sulphydryl group of ACE inhibitors is associated with a number of characteristics including an anti-atherogenic effect, suppression of free radical production and adverse skin reactions [4–6].

Received: 27 April 1993

and in final revised form: 12 October 1993

Corresponding author: Dr. M. Uehara, Department of Metabolic Medicine, Kumamoto University School of Medicine, 1-1-1, Honjo, Kumamoto, 860, Japan

Abbreviations: ACE, Angiotensin converting enzyme; NIDDM, non-insulin-dependent diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; AEP, artificial endocrine pancreas.

Table 1. Clinical characteristics of patients enrolled in the study

	Age (years)	Sex (male/ female)	BMI (kg/m ²)	Duration of diabetes (years)	Σ IRI (nmol/l)	HbA _{1c} (%)	Systolic/diastolic blood pressure (mm Hg)	Treatment
Normotensive healthy subjects (<i>n</i> = 8)	53.2 ± 2.6	6/2	23.0 ± 1.1	–	1.2 ± 0.1	5.4 ± 0.2	130 ± 5.0/80 ± 3.2	–
Hypertensive non- diabetic patients (<i>n</i> = 8)	56.3 ± 4.0	5/3	22.8 ± 1.0	–	1.2 ± 0.1	5.6 ± 0.2	150 ± 4.8 ^a /92 ± 3.4	No drug
Normotensive NIDDM patients (<i>n</i> = 8)	55.5 ± 4.4	5/3	23.9 ± 3.0	10.3 ± 0.6	0.7 ± 0.1 ^a	7.1 ± 0.5 ^a	134 ± 4.2/86 ± 2.8	Diet only or sulphonylurea
Hypertensive NIDDM patients (<i>n</i> = 8)	57.2 ± 7.3	5/3	22.5 ± 2.4	11.2 ± 0.6	0.7 ± 0.1 ^a	8.0 ± 0.8 ^a	156 ± 6.2 ^a /94 ± 3.6	Sulphonylurea

Σ IRI, integrated immunoreactive insulin (IRI) values of five sampling points from 0 to 120 min during 75-g oral glucose tolerance test.

^a *p* < 0.05 vs normotensive healthy subjects

Recent studies indicate that ACE inhibitors can improve insulin sensitivity during either short-term or long-term administration. Rett et al. [7] reported that insulin sensitivity increased in normotensive patients with NIDDM about 20 min after oral administration of captopril. Torlone et al. [8] reported that a 2-day treatment with captopril improved insulin sensitivity in hypertensive NIDDM patients. On the other hand, there are confusing results regarding long-term administration of ACE inhibitors. Paolisso et al. [9] demonstrated that a 2-week treatment using either ACE inhibitors with or without a sulphydryl group increased insulin sensitivities in elderly hypertensive non-diabetic patients. However, other studies have shown that treatments of 3 to 9 weeks using ACE inhibitors without a sulphydryl group did not increase insulin sensitivity in patients with hypertensive NIDDM or IDDM [10–12]. It is possible, therefore, that the presence of the sulphydryl group in ACE inhibitors affects insulin sensitivity. However, the mechanism for this improvement of insulin sensitivity during ACE-inhibition remains to be elucidated. Rett et al. [7] have suggested the contribution of bradykinin, although this is still not widely accepted.

The present study was designed to compare the acute, short-term effects on insulin sensitivity of ACE inhibitors with or without a sulphydryl group using the euglycaemic clamp test in both animal and clinical experiments. In addition, the possible effect of bradykinin on insulin sensitivity was also evaluated.

Materials and methods

Animal experiments

Twenty-four male dogs weighing between 10 and 15 kg were used before and after total pancreatectomy. After the completion of control experiments, they were totally pancreatectomized and then maintained in a moderately hyperglycaemic state for at least 2 weeks using daily subcutaneous long-acting

insulin injections (Monotard MC; Novo Nordisk Pharma. Inc., Copenhagen, Denmark). Their body weights did not change significantly during the experimental periods. Each healthy control or diabetic dog was anaesthetized after an overnight fast with an i.v. bolus infusion of 20 mmol·kg⁻¹ pentobarbital sodium and connected to the AEP (Model STG-22; Nikkiso Co., Ltd., Tokyo, Japan) which we originally developed [13]. A jugular vein catheter was used for insulin and glucose infusions. A femoral vein catheter was used for continuous monitoring of blood glucose by the AEP. A heparinized sterile cannula was also inserted in the opposite femoral vein for sampling venous blood. A hyperinsulinaemic euglycaemic clamp was performed and the glucose infusion rate was continuously monitored for more than 2 h after treatment with an ACE inhibitor.

To evaluate the effectiveness on insulin sensitivity of ACE inhibitors with or without a sulphydryl group, either captopril (ACE inhibitor with a sulphydryl group) or an active metabolite of delapril (ACE inhibitor without a sulphydryl group) dissolved in 0.15 mol/l NaCl at a dose of 3.0 mmol·kg⁻¹ (0.6 mg·kg⁻¹ or 1.5 mg·kg⁻¹, respectively) was injected as a bolus 90 min after the equilibration of glucose infusion rate during the hyperinsulinaemic euglycaemic clamp (experiment 1). Captopril, delapril and enalapril (ACE inhibitor without a sulphydryl group) were also administered orally at a dose of 5.0 mmol·kg⁻¹ (1.0, 2.5 and 2.5 mg·kg⁻¹, respectively), (experiment 2). Compared to captopril, the antihypertensive potencies of delapril and enalapril used in the dog experiments were estimated to be 4 and 12 times more potent, respectively; the study of the pharmacological effects on antihypertensive potencies among these ACE inhibitors has demonstrated that 25 mg of captopril is equivalent to 15 mg of delapril or 5 mg of enalapril [14].

To evaluate the possible effect of bradykinin on insulin sensitivity, a bradykinin antagonist (N- α -adamantaneacetyl-D-Arg-[Hyp³,Thi^{5,8},D-Phe⁷]-bradykinin, 0.5 nmol·kg⁻¹·min⁻¹) was infused 30 min before captopril injection (experiment 3). To confirm the effect of bradykinin on insulin sensitivity, bradykinin was infused i.v. at a low or high dose rate of 0.03 or 0.1 nmol·kg⁻¹·min⁻¹, respectively, 90 min after equilibration of the glucose infusion rate during the hyperinsulinaemic euglycaemic clamp (experiment 4).

Twenty-four dogs were divided into four groups. Each group (*n* = 6) was assigned in either a healthy or diabetic state to one of the four experiments described. For control animals, 0.15 mol·l⁻¹ NaCl in water was infused i.v. Dogs were studied on two or three separate days within a 2-week period before and after pancreatectomy.

Clinical experiments

Eight normotensive healthy subjects and 24 patients were studied to compare the effects on insulin sensitivity of ACE inhibitors with or without a sulphhydryl group. The group of 24 patients consisted of hypertensive non-diabetic patients ($n = 8$), normotensive NIDDM patients ($n = 8$) and hypertensive NIDDM patients ($n = 8$). Their clinical characteristics are shown in Table 1. Hypertension in both the non-diabetic and NIDDM patients was diagnosed using the definition of the United States Joint National Committee which includes patients with more than 140 mm Hg systolic or more than 90 mm Hg diastolic pressure [15]. Patients were on a salt restrictive diet and showed mildly elevated blood pressures. Diabetic patients had been treated with diet therapy or sulphonylurea. The study was approved by the ethical committee at the Kumamoto University School of Medicine. Informed consent was obtained from each subject.

Hyperinsulinaemic euglycaemic clamp tests were conducted, and insulin and glucose were infused through the antecubital vein using the AEP. The ACE inhibitor [$2.0 \text{ mmol} \cdot \text{kg}^{-1}$ of captopril ($0.4 \text{ mg} \cdot \text{kg}^{-1}$), $2.0 \text{ mmol} \cdot \text{kg}^{-1}$ of delapril ($1.0 \text{ mg} \cdot \text{kg}^{-1}$) or $0.67 \text{ mmol} \cdot \text{kg}^{-1}$ of enalapril ($0.3 \text{ mg} \cdot \text{kg}^{-1}$)] was administered orally 90 min after equilibration of the glucose infusion rate during the hyperinsulinaemic euglycaemic clamp. The antihypertensive effect of delapril or enalapril used in clinical experiments was 4 times more potent than that of captopril [14]. Blood samples were taken from the contralateral cannulated cubital veins. Blood pressures and pulse rates were measured before and after administration of ACE inhibitors at 30-min intervals for 2 h. Patients were studied on 3 separate days within a 2-week period.

Euglycaemic clamp study

In animal and clinical experiments, hyperinsulinaemic euglycaemic clamp tests were performed using the method of DeFronzo et al. [16].

The glucose infusion unit of the AEP kept blood glucose at the basal level during the entire study by means of an adequate i.v. glucose infusion. This was programmed by the computer of the system according to the control algorithm: $\text{GIR}(t) = \text{Cp} [\text{BGp} - \text{BG}(t - \tau)] + \text{Cd} [-\Delta \text{BG}(t - \tau)]$, where $\text{GIR}(t)$ is glucose infusion rate; BGp is the projected value of blood glucose concentration; $\text{BG}(t)$ and $\Delta \text{BG}(t)$ are blood glucose concentrations and the rate of change in blood glucose concentration at time t ; Cp and Cd are coefficients for glucose infusion; and τ (min) is the time delay constant for glucose infusion [17]. Optimal parameters of Cp , Cd and τ were selected as 0.2, 20 and 3, respectively. The projected value of blood glucose concentration was set at $5.5 \text{ mmol} \cdot \text{l}^{-1}$. No empirical correction was superimposed to reduce glucose variations during the tests.

After an initial $50 \text{ mU} \cdot \text{kg}^{-1}$ injection of a short-acting insulin (Actrapid MC; Novo Nordisk Pharma. Inc.), it was then continuously infused at a rate of $1.12 \text{ mU} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, during which the blood glucose concentration was held constant at the fasting level or $5.5 \text{ mmol} \cdot \text{l}^{-1}$ by AEP. During the euglycaemic clamp study, venous samples were drawn at the time of -30, 0, 30, 60 and 90 min after the ACE inhibitor or bradykinin administration in animal and clinical experiments, and their plasma glucose, insulin and bradykinin concentrations were measured. The insulin sensitivity index ($10^{-2} \cdot \mu \text{U}^{-1} \cdot \text{ml}^2 \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$), which was calculated by dividing the glucose infusion rate by the incremental plasma insulin and clamped glucose value [18], was evaluated and compared. As a control in each experimental group, the results were expressed as a mean of two determina-

Fig. 1A,B. Effects on plasma concentrations of glucose, insulin and bradykinin, and glucose infusion rates of i.v. or oral administration of ACE inhibitors during hyperinsulinaemic euglycaemic clamp in healthy control dogs. After an initial $50 \text{ mU} \cdot \text{kg}^{-1}$ injection of a short-acting insulin ($\downarrow$), it was then continuously infused at a rate of $1.12 \text{ mU} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$. ACE inhibitors were administered i.v. or orally ($\downarrow$) after the equilibration of glucose infusion rate. (A) Captopril ($\circ$) or an active metabolite of delapril ($\bullet$) was injected as a bolus i.v. at a dose of $3.0 \text{ mmol} \cdot \text{kg}^{-1}$ (0.6 or $1.5 \text{ mg} \cdot \text{kg}^{-1}$, respectively). (B) Captopril ($\circ$), delapril ($\bullet$) or enalapril ($\triangle$) was administered orally at a dose of $5.0 \text{ mmol} \cdot \text{kg}^{-1}$ (1.0 , 2.5 or $2.5 \text{ mg} \cdot \text{kg}^{-1}$, respectively). Values are mean $\pm$ SEM ($n = 6$). * $p < 0.05$, before vs after treatment

tions at -30 and 0 min before administration, and compared with those of a mean of two determinations at 30 and 60 min after administration of ACE inhibitors.

Assays

Plasma glucose concentrations were measured using the glucose oxidase method (Autoanalyzer; Technicon Instruments Corp., Tarrytown, NY, USA) and plasma insulin concentrations were determined by radioimmunoassay (Eiken Immunochemical Laboratory, Tokyo, Japan).

Plasma bradykinin concentrations were measured by radioimmunoassay (Otsuka Assay Laboratory, Tokushima, Japan) [19]. Plasma samples were treated with proteinase inhibitors and EDTA, and then frozen until assayed. The detection limit was $2.5 \text{ pmol} \cdot \text{l}^{-1}$. Intra- and inter-assay variations were 2.2–6.3 and 4.9–12.6%, respectively.

Captopril, delapril and its active metabolite, and enalapril maleate were kindly supplied by Sankyo Co. Ltd. (Tokyo, Japan), Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) and Banyu Pharmaceutical Co. Ltd. (Tokyo, Japan) respectively. Bradykinin and bradykinin antagonist (N- α -adamantaneacetyl-D-Arg-[Hyp³,Thi^{5,8},D-Phe⁷]-bradykinin) [20] were purchased from Sigma Chemical Co. Ltd. (St. Louis, Mo., USA).

Table 2. Effects on insulin sensitivity indices and plasma bradykinin concentrations of i. v. or oral administration of ACE inhibitors, bradykinin antagonist or bradykinin in dog experiments

Treatment			Insulin sensitivity index (10 ⁻² ·μU ⁻¹ ·ml ² ·kg ⁻¹ ·min ⁻¹)		Plasma bradykinin concentration (pmol·l ⁻¹)	
			Before	After	Before	After
<i>Healthy control dogs</i>						
Saline	(i. v. 0.15 mol·l ⁻¹)	6	12.6±0.2	12.7±0.2	10.7±0.5	10.6±0.5
Captopril	(i. v. 3.0 mmol·kg ⁻¹)	6	12.8±0.1	17.3±0.2 ^b	10.2±1.4	23.9±2.4 ^b
Active metabolite of delapril	(i. v. 3.0 mmol·kg ⁻¹)	6	12.6±0.1	14.1±0.1	10.3±0.8	12.6±0.9
Captopril	(oral, 5.0 mmol·kg ⁻¹)	6	13.2±0.2	17.1±0.4 ^b	10.6±0.7	24.2±1.2 ^b
Delapril	(oral, 5.0 mmol·kg ⁻¹)	6	13.8±0.2	15.1±0.3	10.7±0.4	12.9±0.7
Enalapril	(oral, 5.0 mmol·kg ⁻¹)	6	12.9±0.2	14.0±0.4	10.0±0.4	12.1±0.7
Captopril with bradykinin antagonist	(i. v. 3.0 mmol·kg ⁻¹) (i. v. 0.5 nmol·kg ⁻¹ ·min ⁻¹)	6	12.9±0.1	13.1±0.3		
Bradykinin	(i. v. 0.03 nmol·kg ⁻¹ ·min ⁻¹)	6	12.7±0.2	14.2±0.5	10.8±0.7	14.1±2.5
Bradykinin	(i. v. 0.1 nmol·kg ⁻¹ ·min ⁻¹)	6	12.6±0.2	18.3±0.8 ^b	10.6±0.7	34.5±4.2 ^b
<i>Depancreatized diabetic dogs</i>						
Saline	(i. v. 0.15 mol·l ⁻¹)	6	10.3±0.2	10.2±0.4	10.1±0.3	10.0±0.5
Captopril	(i. v. 3.0 mmol·kg ⁻¹)	6	10.5±0.3 ^a	16.4±0.5 ^b	9.8±0.4	22.9±2.5 ^b
Active metabolite of delapril	(i. v. 3.0 mmol·kg ⁻¹)	6	9.7±0.3 ^a	12.5±0.4	10.7±0.5	12.5±0.6
Captopril	(oral, 5.0 mmol·kg ⁻¹)	6	9.7±0.3 ^a	15.2±0.4 ^b	9.8±0.4	22.6±2.8 ^b
Delapril	(oral, 5.0 mmol·kg ⁻¹)	6	9.8±0.3 ^a	11.2±0.4	9.6±0.4	11.5±0.5
Enalapril	(oral, 5.0 mmol·kg ⁻¹)	6	9.0±0.3 ^a	10.8±0.4	9.1±0.3	10.9±0.5
Captopril with bradykinin antagonist	(i. v. 3.0 mmol·kg ⁻¹) (i. v. 0.5 nmol·kg ⁻¹ ·min ⁻¹)	6	10.4±0.1 ^a	10.0±0.3		
Bradykinin	(i. v. 0.03 nmol·kg ⁻¹ ·min ⁻¹)	6	10.2±0.3 ^a	12.8±0.4	10.2±0.5	13.1±1.1
Bradykinin	(i. v. 0.1 nmol·kg ⁻¹ ·min ⁻¹)	6	10.5±0.3 ^a	16.9±0.5 ^b	9.4±0.4	26.3±2.7 ^b

ACE inhibitors at a dose of $1.0 \text{ mmol} \cdot \text{kg}^{-1}$ are equivalent to 0.2, 0.5 and $0.5 \text{ mg} \cdot \text{kg}^{-1}$ in captopril, delapril and enalapril, respectively.

^a $p < 0.05$ vs healthy control dogs. ^b $p < 0.05$ vs before treatment

Statistical analysis

All data are expressed as mean $\pm$ SEM. Statistical analysis was performed using the Student's *t*-test.

Results

Animal experiments

During hyperinsulinaemic euglycaemic clamp studies in the dog experiments, plasma glucose concentrations were clamped at $5.3 \pm 0.2 \text{ mmol} \cdot \text{l}^{-1}$ (5.2 ± 0.2 and $5.4 \pm 0.2 \text{ mmol} \cdot \text{l}^{-1}$ in healthy control and depancreatized diabetic dogs, respectively). Plasma insulin concentrations were clamped at $550 \pm 35 \text{ pmol} \cdot \text{l}^{-1}$ (559 ± 41 and $545 \pm 35 \text{ pmol} \cdot \text{l}^{-1}$ in the two groups, respectively).

Effect on insulin sensitivity of ACE inhibitors. Figure 1 shows the effect on plasma concentration of glucose, insulin and bradykinin, and glucose infusion rates of i. v. or oral administration of ACE inhibitors during

hyperinsulinaemic euglycaemic clamp tests in healthy control dogs. Table 2 summarizes the effects on insulin sensitivity indices and plasma bradykinin concentrations of ACE inhibitors, bradykinin antagonist or bradykinin in healthy control and depancreatized diabetic dogs.

As shown in Figure 1 and Table 2, in healthy control dogs, glucose infusion rates increased from the basal steady-state levels of 31.3 ± 2.1 to the significantly higher levels of $42.2 \pm 3.9 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ at 20 min after i. v. administration or from 34.4 ± 3.2 to $49.4 \pm 4.7 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ at 30 min after oral administration of captopril, respectively. Accordingly, insulin sensitivity indices increased significantly from 12.8 ± 0.1 to 17.3 ± 0.2 after i. v. administration or from 13.2 ± 0.2 to $17.1 \pm 0.4 \cdot 10^{-2} \cdot \mu\text{U}^{-1} \cdot \text{ml}^2 \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ after oral administration of captopril, respectively (Table 2). Concomitantly with these increases in insulin sensitivity indices, plasma bradykinin concentrations increased significantly from 10.2 ± 1.4 to $23.9 \pm 2.4 \text{ pmol} \cdot \text{l}^{-1}$ after i. v. administration or from

Table 3. Effects on insulin sensitivity indices and plasma bradykinin concentrations of oral administration of ACE inhibitors in clinical experiments

Treatment			Insulin sensitivity index ($10^{-2} \cdot \mu\text{U}^{-1} \cdot \text{ml}^2 \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$)		Plasma bradykinin concentration ($\text{pmol} \cdot \text{l}^{-1}$)	
			Before	After	Before	After
<i>Normotensive healthy subjects</i>						
Captopril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	13.7 ± 0.4	17.3 ± 0.5^c	10.6 ± 0.4	22.8 ± 2.3^c
Delapril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	13.4 ± 0.4	15.4 ± 0.4	11.2 ± 0.4	13.3 ± 0.5
Enalapril	($0.67 \text{ mmol} \cdot \text{kg}^{-1}$)	8	13.1 ± 0.4	14.9 ± 0.6	11.5 ± 0.6	13.0 ± 1.1
<i>Hypertensive non-diabetic patients</i>						
Captopril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	9.1 ± 0.6^a	12.8 ± 0.7^c	10.2 ± 0.4	22.3 ± 2.0^c
Delapril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	9.7 ± 0.3^a	10.8 ± 0.4	10.6 ± 0.4	12.4 ± 0.3
Enalapril	($0.67 \text{ mmol} \cdot \text{kg}^{-1}$)	8	9.6 ± 0.3^a	10.0 ± 0.5	10.1 ± 0.5	11.9 ± 0.4
<i>Normotensive NIDDM patients</i>						
Captopril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	7.4 ± 0.4^a	9.2 ± 0.7^c	9.2 ± 0.3	20.2 ± 1.8^c
Delapril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	6.8 ± 0.2^a	8.4 ± 0.2	9.8 ± 0.5	11.6 ± 0.5
Enalapril	($0.67 \text{ mmol} \cdot \text{kg}^{-1}$)	8	6.5 ± 0.2^a	7.6 ± 0.3	9.7 ± 0.5	11.4 ± 0.6
<i>Hypertensive NIDDM patients</i>						
Captopril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	$5.0 \pm 0.4^{a,b}$	7.5 ± 0.5^c	8.6 ± 0.4	19.6 ± 1.8^c
Delapril	($2.0 \text{ mmol} \cdot \text{kg}^{-1}$)	8	$5.0 \pm 0.3^{a,b}$	6.6 ± 0.3	9.3 ± 0.4	11.8 ± 0.4
Enalapril	($0.67 \text{ mmol} \cdot \text{kg}^{-1}$)	8	$5.2 \pm 0.3^{a,b}$	6.2 ± 0.7	8.9 ± 0.3	10.2 ± 0.3

ACE inhibitors at a dose of 1.0 mmol · kg⁻¹ are equivalent to 0.2, 0.5 and 0.5 mg · kg⁻¹ in captopril, delapril and enalapril, respectively.

^a $p < 0.05$ vs before treatment in normotensive healthy subjects. ^b $p < 0.05$ vs before treatment in normotensive NIDDM patients.

^c $p < 0.05$ vs before treatment

10.6 ± 0.7 to 24.2 ± 1.2 pmol · l⁻¹ after oral administration of captopril, respectively. In comparison, i.v. administration of an active metabolite of delapril and oral administration of either delapril or enalapril showed slight, but not significant increases in insulin sensitivity indices and plasma bradykinin concentrations.

In depancreatized diabetic dogs, insulin sensitivity indices were 10.0 ± 0.2 10⁻² · μU⁻¹ · ml² · kg⁻¹ · min⁻¹. These values were significantly lower than those of healthy control dogs (12.9 ± 0.1 10⁻² · μU⁻¹ · ml² · kg⁻¹ · min⁻¹; mean of 24 dogs). As in healthy control dogs, insulin sensitivity indices improved significantly in depancreatized diabetic dogs after i.v. or oral administration of captopril. These improvements in insulin sensitivities were concomitant with the increases in plasma bradykinin concentrations. Again, i.v. injection of an active metabolite of delapril and oral administration of enalapril or delapril showed slight, but not significant effects on insulin sensitivity indices and plasma bradykinin concentrations.

Effect on insulin sensitivity of bradykinin antagonist and bradykinin. To test the possible effect of bradykinin on the improvement of insulin sensitivities, a bradykinin antagonist (N-α-adamantaneacetyl-D-Arg[Hyp³,Thi^{5,8},D-Phe⁷]-bradykinin) was infused i.v. 30 min before captopril injection in healthy control and depancreatized diabetic dogs.

In both healthy control and depancreatized diabetic dogs, administration of the bradykinin antagonist abolished the effects of captopril on insulin sensitivity. In these experiments, venous plasma bradykinin concentrations could not be determined because anti-brady-

kinin antibody in the bradykinin assay system cross-reacted with the bradykinin antagonist.

Furthermore, to reveal the direct action of bradykinin on insulin sensitivity, bradykinin was infused i.v. into both healthy control and diabetic dogs. Intravenous administrations of bradykinin at concentrations of 0.03 and 0.1 nmol · kg⁻¹ · min⁻¹ increased plasma bradykinin concentrations to the levels of 14.1 ± 2.5 and 34.5 ± 4.2 pmol · l⁻¹ in healthy control dogs and 13.1 ± 1.1 and 26.3 ± 2.7 pmol · l⁻¹ in diabetic dogs. Concomitant with the increase in plasma bradykinin concentrations, insulin sensitivity indices increased significantly after i.v. administration of bradykinin.

Clinical experiments

During hyperinsulinaemic euglycaemic clamp studies in clinical experiments, plasma glucose concentrations were clamped at 5.0 ± 0.3 mmol · l⁻¹ (5.2 ± 0.2, 4.9 ± 0.2, 4.8 ± 0.3 and 5.2 ± 0.4 mmol · l⁻¹ in normotensive healthy subjects, hypertensive non-diabetic patients, normotensive NIDDM patients and hypertensive NIDDM patients, respectively). Plasma insulin concentrations were clamped at 607 ± 48 pmol · l⁻¹ (607 ± 48, 607 ± 41, 600 ± 35 and 614 ± 41 pmol · l⁻¹ for these four groups, respectively).

In normotensive healthy subjects and normotensive NIDDM patients, after administration of ACE inhibitors blood pressure did not change significantly. However, in hypertensive non-diabetic patients, blood pressure decreased significantly from 150 ± 5/92 ± 3, 152 ±

4/95 $\pm$ 3 and 150 $\pm$ 5/92 $\pm$ 3 to 135 $\pm$ 4/83 $\pm$ 2, 124 $\pm$ 6/79 $\pm$ 6 and 122 $\pm$ 5/80 $\pm$ 4 mm Hg ($p < 0.01$) at 60 min after oral administration of captopril, delapril and enalapril, respectively. Similarly, in hypertensive NIDDM patients, blood pressures decreased significantly from 156 $\pm$ 6/96 $\pm$ 4, 154 $\pm$ 6/94 $\pm$ 4 and 155 $\pm$ 6/93 $\pm$ 4 to 141 $\pm$ 7/86 $\pm$ 5, 134 $\pm$ 8/84 $\pm$ 5 and 132 $\pm$ 4/86 $\pm$ 4 mm Hg ($p < 0.01$) at 60 min in captopril, delapril and enalapril, respectively. However, ACE inhibitors did not influence the pulse rates in all four groups.

Effects on insulin sensitivity indices and plasma bradykinin concentrations of ACE inhibitors in normotensive and hypertensive patients are summarized in Table 3.

Insulin sensitivity indices decreased in the following order: normotensive healthy subjects, hypertensive non-diabetic patients, normotensive NIDDM patients and hypertensive NIDDM patients; 13.7 $\pm$ 0.4, 9.1 $\pm$ 0.6, 7.4 $\pm$ 0.4 and 5.0 $\pm$ 0.4 $10^{-2} \cdot \mu\text{U}^{-1} \cdot \text{ml}^2 \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, respectively. Insulin sensitivity indices in hypertensive patients were significantly lower than those in normotensive patients.

Oral administration of captopril (2.0 mmol $\cdot$ kg $^{-1}$, 0.4 mg $\cdot$ kg $^{-1}$) significantly increased insulin sensitivity indices from basal values to 17.3 $\pm$ 0.5, 12.8 $\pm$ 0.7, 9.2 $\pm$ 0.7 and 7.5 $\pm$ 0.5 $10^{-2} \cdot \mu\text{U}^{-1} \cdot \text{ml}^2 \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ in normotensive healthy subjects, hypertensive non-diabetic patients, normotensive NIDDM patients and hypertensive NIDDM patients, respectively. Concomitantly, plasma bradykinin concentrations significantly increased after oral administration of captopril from 10.6 $\pm$ 0.4, 10.2 $\pm$ 0.4, 9.2 $\pm$ 0.3 and 8.6 $\pm$ 0.4 pmol $\cdot$ l $^{-1}$ to 22.8 $\pm$ 2.3, 22.3 $\pm$ 2.0, 20.2 $\pm$ 1.8 and 19.6 $\pm$ 1.8 pmol $\cdot$ ml $^{-1}$ in normotensive healthy subjects, hypertensive non-diabetic patients, normotensive NIDDM patients and hypertensive NIDDM patients, respectively. By contrast, oral administration of enalapril or delapril showed slight, but not significant effects on insulin sensitivity indices and plasma bradykinin concentrations.

Discussion

DeFronzo et al. [21] elucidated the decreased insulin sensitivity in patients with impaired glucose tolerance or NIDDM using the euglycaemic clamp technique. Furthermore, using the same technique, Ferrannini et al. [22] demonstrated decreased insulin sensitivities in patients with essential hypertension. Compatible with their findings, the present study in both animal and clinical experiments demonstrated that insulin sensitivity was decreased in the hypertensive state whether or not glucose tolerance was impaired, and that insulin sensitivity in diabetes was significantly lower than that observed in the non-diabetic state. Insulin-stimulated glucose utilization in peripheral tissues is known to decrease significantly in hypertensive patients [22, 23]. Nevertheless, hypertension is treated with antihyper-

tensive drugs which may have adverse metabolic effects, and in particular may inhibit insulin secretion and impair the actions of insulin [2]. Among the antihypertensive drugs, however, ACE-inhibitors in addition to their antihypertensive effect, may improve insulin sensitivity.

Currently available ACE inhibitors were divided into two categories, those with (captopril) or without a sulphhydryl group (delapril or enalapril). The antihypertensive effect of ACE inhibitors [delapril (1.0 mg $\cdot$ kg $^{-1}$) or enalapril (0.3 mg $\cdot$ kg $^{-1}$)] used in our clinical experiments was 4 times more potent than that of captopril (0.4 mg $\cdot$ kg $^{-1}$), comparing the pharmacological data of these ACE inhibitors [14]. From these pharmacokinetic data, T_{max} values (time to the maximum serum concentration) were 0.86 h for captopril, 1 h for enalapril and 4 h for enalapril diacid, more potent active metabolite. The T_{max} values of delapril and delapril diacid were similar to those of enalapril. With delapril or enalapril, however, plasma levels after oral administration of these agents increased as fast as those of captopril and were sustained longer than those of captopril [14]. As a result, more significant blood pressure lowering effects were observed after oral administration of delapril or enalapril, compared to those after captopril administration.

It is widely accepted that captopril has a beneficial effect on insulin sensitivity [7, 8]. However, there have been confusing results as to ACE inhibitors without a sulphhydryl group (delapril or enalapril). Using the minimal models proposed by Bergman et al. [18, 24], Paolisso et al. [9] reported that a 2-week treatment with ACE inhibitors either with or without a sulphhydryl group improved insulin sensitivity in elderly hypertensive non-diabetic patients. On the other hand, Seefeldt et al. [10] demonstrated that treatment with enalapril had no effect on glucose metabolism in diabetic patients using the glucose clamp technique. In our evaluation of the acute effect on insulin sensitivity of ACE inhibitors with or without a sulphhydryl group, we have clearly demonstrated in both dog and clinical experiments that ACE inhibitors with a sulphhydryl group could significantly improve insulin sensitivity. This increase and/or improvement in insulin sensitivity after captopril administration, either intravenously or orally, was concomitant with a significant increase in plasma bradykinin concentration. However, ACE inhibitors without a sulphhydryl group showed slight, but not significant effects on insulin sensitivities and plasma bradykinin concentrations. From these experiments, it was suggested that the increase in plasma bradykinin concentrations might play a significant role in the improvement of insulin sensitivity.

ACE inhibitors without a sulphhydryl group have been developed to eliminate the side effects caused by the sulphhydryl group in captopril. Captopril contains a modified proline molecule with a mercapto moiety that binds with the zinc atom of the metalloenzyme ACE,

thus inactivating ACE [25]. Enalapril, delapril and other second-generation ACE inhibitors differ from captopril in that they compete with the renin substrate for ACE binding sites [25]. The reason why ACE inhibitors with a sulphydryl group have more potent action on the improvement in insulin sensitivity, concomitant with a significant increase in plasma bradykinin concentrations, despite similar antihypertensive and cardiovascular effects remains unanswered. The possibility cannot be excluded that plasma bradykinin concentrations increase in the arterial blood stream after administration of ACE inhibitors without a sulphydryl group. Since the half-life of secreted bradykinin is less than 60 s, plasma concentrations of bradykinin might not be high enough to demonstrate a significant increase in insulin sensitivity after administration of ACE inhibitors without a sulphydryl group (delapril or enalapril). After captopril is metabolized in the liver, the disulphide dimer has been reported to enhance the bradykinin-induced vasopressor response, although captopril disulphides are not themselves significant inhibitors of ACE [26–28]. Thus, the disulphide dimer produced after captopril administration might possibly protect further degradation of bradykinin, resulting in prolongation of the half-life.

In our present dog and clinical experiments, increases in insulin sensitivity indices after administration of an ACE inhibitor with a sulphydryl group were concomitant with a significant increase in plasma bradykinin concentration. In dog experiments, an infusion of a bradykinin antagonist 30 min before captopril injection abolished the captopril effect on insulin sensitivity. When testing the direct action of bradykinin on insulin sensitivity by infusing bradykinin at the same levels as observed after captopril injection, it was found that insulin sensitivity indices significantly increased. These findings were in agreement with reports by Hartl et al. [29] who described that bradykinin infused at the rate of $0.03 \text{ nmol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ had a positive effect on insulin sensitivity in insulin-resistant post-operative and NIDDM patients without any systemic haemodynamic changes [30]. Therefore, plasma bradykinin concentrations after captopril administration might have a significant role in the improvement of insulin sensitivity.

The influence of ACE inhibitors with a sulphydryl group on insulin sensitivity might be explained through haemodynamic and/or hormonal hypotheses. Vasodilation or constriction may significantly affect peripheral glucose uptake [31]. As suggested by Bergman et al. [24], vasodilation decreases the distance between feeding capillaries (capillary recruitment) with a secondary improvement in the insulin concentration gradient between the capillary and surrounding muscle. This haemodynamic hypothesis is supported by the finding of Kodama et al. [32] who have demonstrated that an increase in forearm blood flow may play a key role in the increase in glucose handling after captopril admin-

istration. As a potent vasodilator, increased plasma bradykinin concentrations after captopril might also be responsible for vasodilation.

As to the hormonal hypothesis, after ACE-inhibition, Dietze et al. [33] and Jauch et al. [34] reported that the reduced degradation of bradykinin might exert an insulin-like activity. In our preliminary experiments with adipocytes isolated from dog adipose tissue, increases in glucose uptake and autophosphorylation of insulin receptors were observed in cells incubated with bradykinin and insulin, without any significant increase in receptor numbers.

In the clinical experiments, we studied non-obese NIDDM patients, a patient group commonly observed in Japan. Further studies are necessary to elucidate the beneficial effect of captopril on insulin sensitivity in obese NIDDM patients with or without hypertension, who show much more insulin resistance than non-obese NIDDM patients.

In conclusion, our dog and clinical experiments demonstrate that ACE inhibitors with a sulphydryl group have more potent action on insulin sensitivity than those without a sulphydryl group. This beneficial effect on insulin sensitivity might be mediated through plasma bradykinin levels. Captopril, which is an ACE inhibitor with a sulphydryl group may be the best choice for the treatment of diabetic patients with hypertension, unless severe diabetic nephropathy is present.

Acknowledgement. We thank Mr. K. Ichinose for his skillful work.

References

1. Ferrannini E, Galvan AQ (1992) Hyperinsulinemia, insulin resistance, and blood pressure. *Hypertens Res* 15: 67–75
2. Stein PP, Black HR (1991) Drug treatment of hypertension in patients with diabetes mellitus. *Diabetes Care* 14: 425–448
3. Zusman RM (1987) Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. *Am J Kid Dis* 10 [Suppl 1]: 13–23
4. Chobanian AV, Haudenschild CC, Nickerson C, Drago R (1989) Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. *Hypertension* 15: 327–331
5. Mehta JL, Nicolini FA, Lawson DL (1990) Sulphydryl group in angiotensin converting enzyme inhibitors and superoxide radical formation. *J Cardiovasc Pharmacol* 16: 847–849
6. Gavras H, Gavras I (1988) Angiotensin converting enzyme inhibitors properties and side effects. *Hypertension* 11 [Suppl II]: 37–41
7. Rett K, Lotz N, Wicklmayr M et al. (1988) Improved insulin action by ACE inhibitor in type II diabetes. *Dtsch Med Wochenschr* 113: 243–249
8. Torlone E, Rambotti AM, Periello G et al. (1991) ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. *Diabetologia* 34: 119–125

9. Paolisso G, Gambaldella A, Verza M, D'Amore A, Sgambato S, Varricchio M (1992) ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. *J Hum Hypertens* 6: 175–179
10. Seefeldt T, Ørskov L, Mengel A et al. (1990) Lack of effects on angiotensin-converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 diabetes. *Diabetes Med* 7: 700–704
11. Bak JF, Gerdes LU, Sørensen NS, Pedersen O (1992) Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. *Am J Med* 92: 69–72
12. Moore MP, Elliott TW, Nicholls MG (1988) Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. *Diabetes Care* 11: 397–401
13. Shichiri M, Kawamori R, Abe H (1979) Normalization of the paradoxical secretion of glucagon in diabetics who were controlled by the artificial beta cell. *Diabetes* 28: 272–275
14. Shionoiri H, Yasuda G, Ikeda A et al. (1987) Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. *Clin Pharmacol Ther* 41: 74–79
15. Joint National Committee (1988) The 1988 report of the joint national committee on detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 148: 1023–1038
16. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 237: E214–E223
17. Shichiri M, Kawamori R (1985) Optimized algorithms for closed-loop glycemic control systems. In: Beyer J, Albisser M, Schrezenmeir J, Lehmann L (eds) *Computer systems for insulin adjustment in diabetes mellitus*. Panscienta-Verlag, Hedingen, pp 171–183
18. Finegood DT, Pacini G, Bergman RN (1984) The insulin sensitivity index: correlation in dogs between values determined from the intravenous glucose tolerance test and the euglycemic glucose clamp. *Diabetes* 33: 362–368
19. Minami M, Togashi H, Sano M et al. (1983) Plasma bradykinin concentration in patients with essential hypertension, effort angina and other cardiac disease. *Folia Endocrinol Jpn* 82: 159–169
20. Lammek B, Wang Y, Gavras I, Gavras H (1990) A highly potent bradykinin antagonist with no agonist activity. *Peptide* 11: 1041–1043
21. DeFronzo RA (1988) Lilly lecture 1987: The triumvirate: β -cell, muscle, liver: a collusion responsible for NIDDM. *Diabetes* 36: 667–687
22. Ferrannini E, Buzzigoli G, Bonadonna R et al. (1987) Insulin resistance in essential hypertension. *N Engl J Med* 317: 350–357
23. Pollare T, Lithell H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. *N Engl J Med* 321: 868–873
24. Bergman RN, Hope ID, Yang YJ et al. (1989) Assessment of insulin sensitivity in vivo: a critical review. *Diabetes Metab Rev* 5: 411–429
25. Patchett AA, Harris E, Tristram EW et al. (1980) A new class of angiotensin-converting enzyme inhibitors. *Nature* 288: 280–283
26. O'Hara N, Ono H, Hashimoto K (1982) Potentiation of bradykinin-induced decrease of blood pressure in dogs by SQ 14,551, the disulfide metabolite of captopril. *Jpn J Pharmacol* 32: 934–937
27. Drummer OH, Kourtis S, Jarrott B (1985) Inhibition of angiotensin converting enzyme by metabolites of captopril. *Clin Exp Pharmacol Physiol [Suppl]* 9: 12–16
28. Drummer OH, Kourtis S (1988) Bradykinin-potentiating activity of captopril disulphide dimer (SQ 14551). *Eur J Pharmacol* 153: 11–17
29. Hartl WH, Jauch KW, Herndon DN, Cohnert TU, Wolfe RR, Schidberg FW (1990) Effect of low-dose bradykinin on glucose metabolism and nitrogen balance in surgical patients. *Lancet* 335: 69–71
30. Wicklmayr M, Dietze G, Günther B, Boettger I, Mayer L, Janetschek P (1979) Improvement in glucose assimilation and protein degradation by bradykinin in maturity onset diabetics and in surgical patients. *Kinins II*: 569–576
31. Laasko M, Edelman V, Brecjtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese men. A novel mechanism for insulin resistance. *J Clin Invest* 85: 1844–1852
32. Kodama J, Kitayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J (1990) Effect of captopril on glucose concentration: possible role of augmented postprandial forearm blood flow. *Diabetes Care* 13: 1109–1111
33. Dietze G (1982) Modulation of the action of insulin in relation to the energy state in skeletal muscle. Possible involvement of kinins and prostaglandins. *Mol Cell Endocrinol* 25: 127–149
34. Jauch KW, Günther B, Hartl W, Rett K, Wicklmayr M, Dietze G (1986) Improvement of impaired post-operative insulin action by bradykinin. *Biochem Chem Hoppe Seyler* 367: 207–210